Sonidegib
Sonidegib (INN) or erismodegib (USAN), also known as LDE225, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis.[1][2] It has been investigated as a potential treatment for:
- Pancreatic cancer[3][4][5][6]
- Breast cancer[7][8]
- Basal cell carcinoma of the skin[9][10][11]
- Small cell lung cancer[12]
- Medulloblastoma[13][14]
- Advanced solid tumours (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)[15][16][17]
- Acute leukaemia[18]
- Chronic myeloid leukaemia[19]
- Myelofibrosis and essential thrombocythaemia[20]
It has demonstrated significant efficacy against melanoma in vitro and in vivo.[21] It also demonstrated efficacy in a mouse model of pancreatic cancer.[22]
Reference list
The article on Sonidegib is a stub. YOU can help Wikimd by expanding it!
Medication resources
Learn more
WikiMD Resources - Sonidegib
Science to Social Media | |
|---|---|
WikiMD Resources on Sonidegib | |
| Uptodate | |
| Medline | |
| Pub Med | |
| Wikipedia | |
| About | |
 Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP* |
Quick links: Medicine Portal | Encyclopedia | Gray's Anatomy | Topics | Diseases | Drugs | Wellness | Obesity | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Sonidegib">Sonidegib</a>
- Individual results may vary for weight loss from our sponsors.